caa a22 4500 445331313 CHVBK 20180317142738.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s10689-011-9425-2 doi (NATIONALLICENCE)springer-10.1007/s10689-011-9425-2 BRCA1/2 genetic testing uptake and psychosocial outcomes in men [Elektronische Daten] [Kristi Graves, Rhoda Gatammah, Beth Peshkin, Ayelet Krieger, Christy Gell, Heiddis Valdimarsdottir, Marc Schwartz] Few studies have quantitatively evaluated the uptake and outcomes of BRCA1/2 genetic counseling and testing in men. We conducted a prospective longitudinal study to describe and compare uptake of and psychosocial outcomes following BRCA1/2 testing in a sample of men and women at high-risk for carrying a BRCA1/2 mutation. Men (n=98) and women (n=243) unaffected with cancer completed baseline assessments prior to genetic counseling and testing and then 6- and 12-months post-testing. Most men (n=94; 95.9%) opted to have genetic testing, of whom 44 received positive BRCA1/2 genetic test results and 50 received true negative results. Among women, 93.4% had genetic testing, of whom 79 received positive results and 148 received negative results. In multivariate models, male BRCA1/2 carriers reported significantly higher genetic testing distress (6-months: Z=4.48, P<0.0001; 12-months: Z=2.78, P<0.01) than male non-carriers. After controlling for baseline levels of distress, no statistically significant differences emerged between male and female BRCA1/2 carriers in psychological distress at 12-months post-testing, although absolute differences were evident over time. Predictors of distress related to genetic testing among male carriers at 12-months included higher baseline cancer-specific distress (Z=4.73, P<0.0001) and being unmarried (Z=2.18, P<0.05). Similarly, baseline cancer-specific distress was independently associated with cancer-specific distress at 6- (Z=3.66, P<0.001) and 12-months (Z=4.44, P<0.0001) post-testing among male carriers. Clinically, our results suggest that pre-test assessment of distress and creation of educational materials specifically tailored to the needs and concerns of male carriers may be appropriate in this important but understudied high-risk group. Springer Science+Business Media B.V., 2011 BRCA1/2 nationallicence Cancer risk nationallicence Genetic testing nationallicence Male female comparisons nationallicence Men nationallicence Psychosocial outcomes nationallicence Test uptake nationallicence Graves Kristi Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Suite 4100, 20007, Washington, DC, USA aut Gatammah Rhoda University of the District of Columbia, Washington, DC, USA aut Peshkin Beth Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Suite 4100, 20007, Washington, DC, USA aut Krieger Ayelet Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Suite 4100, 20007, Washington, DC, USA aut Gell Christy Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Suite 4100, 20007, Washington, DC, USA aut Valdimarsdottir Heiddis Mount Sinai School of Medicine, New York, NY, USA aut Schwartz Marc Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Suite 4100, 20007, Washington, DC, USA aut Familial Cancer Springer Netherlands 10/2(2011-06-01), 213-223 1389-9600 10:2<213 2011 10 10689 https://doi.org/10.1007/s10689-011-9425-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10689-011-9425-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Graves Kristi Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Suite 4100, 20007, Washington, DC, USA aut NATIONALLICENCE 700 1- Gatammah Rhoda University of the District of Columbia, Washington, DC, USA aut NATIONALLICENCE 700 1- Peshkin Beth Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Suite 4100, 20007, Washington, DC, USA aut NATIONALLICENCE 700 1- Krieger Ayelet Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Suite 4100, 20007, Washington, DC, USA aut NATIONALLICENCE 700 1- Gell Christy Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Suite 4100, 20007, Washington, DC, USA aut NATIONALLICENCE 700 1- Valdimarsdottir Heiddis Mount Sinai School of Medicine, New York, NY, USA aut NATIONALLICENCE 700 1- Schwartz Marc Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Suite 4100, 20007, Washington, DC, USA aut NATIONALLICENCE 773 0- Familial Cancer Springer Netherlands 10/2(2011-06-01), 213-223 1389-9600 10:2<213 2011 10 10689 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer